Selangor Journal
Vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. — Picture by REUTERS

Covid-19: CanSino’s single dose booster vaccine approved

KUALA LUMPUR, June 30 — The Health Ministry (MOH) has approved CanSino’s single-dose Convidecia vaccine to be used as a heterologous booster with all Covid-19 primary vaccines in Malaysia.

Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc in a statement today said the vaccine was approved for adults aged 18 years and older, regardless of the type of vaccine they received during their earlier Covid-19 vaccination.

The statement also stated Convidecia will be given as a booster dose after at least three months of recipients receiving the second dose of their primary vaccination

“It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca Covid-19 vaccines,” the statement said.

In the same statement, SGB’s deputy group managing director Datuk Dr Mohd Nazlee Kamal said recent studies in China showed the usage of Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralizing antibody responses.

In addition, he said the vaccine’s safety profile in real-life usage was also backed by the Mexican health authorities’ Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) Report released recently.

— Bernama

Top Picks

Freedom of speech guaranteed, but within legal limits — Fahmi Fadzil

Editor Selangor Journal

DID issues flood preparedness notice for Perak, Selangor

Editor Selangor Journal

Four men nabbed in RM13 million drug bust

Editor Selangor Journal